Overcoming challenges in treating autoimmuntity: Development of tolerogenic immune-modifying nanoparticles
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Autoimmune diseases, such as celiac disease, multiple sclerosis, and type 1 diabetes, are leading causes of morbidity and mortality in the United States. In these disease states, immune regulatory mechanisms fail that result in T and B cell-mediated destruction of self-tissues. The known role of T cells in mediating autoimmune diseases has led to the emergence of numerous therapies aimed at inactivating T cells, however successful ‘tolerance-inducing’ strategies have not yet emerged for approved standard-of-care clinical use. In this review, we describe relevant examples of antigen-specific tolerance approaches that have been applied in clinical trials for human diseases. Furthermore, we describe the evolution of biomaterial approaches from cell-based therapies to induce immune tolerance with a focus on the Tolerogenic Immune-Modifying nanoParticle (TIMP) platform. The TIMP platform can be designed to treat various autoimmune conditions and is currently in clinical trials testing its ability to reverse celiac disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier
Makadia, H. K., & Siegel, S. J. (2011) · Polymers · doi:10.3390/polym3031377 · Cited by 4,816
Scavenger receptors in homeostasis and immunity
Canton, J., Neculai, D., & Grinstein, S. (2013) · Nature Reviews Immunology · doi:10.1038/nri3515 · Cited by 838
Epitope spreading initiates in the CNS in two mouse models of multiple sclerosis
McMahon, E. J., Bailey, S. L., Castenada, C. V., Waldner, H., & Miller, S. D. (2005) · Nature Medicine · doi:10.1038/nm1202 · Cited by 694
Self-citation
Cited by
Recent progress in targeted delivery vectors based on biomimetic nanoparticles
Chen, L., Hong, W., Ren, W., Xu, T., Qian, Z., & He, Z. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00631-2 · Cited by 374
Novel approaches for vaccine development
Gebre, M. S., Brito, L. A., Tostanoski, L. H., Edwards, D. K., Carfi, A., & Barouch, D. H. (2021) · Cell · doi:10.1016/j.cell.2021.02.030 · Cited by 347
“, 2018; Wang and Mooney, 2018) or to combat autoimmune diseases (Gammon and Jewell, 2019; Northrup et al., 2016; Pearson et al., 2019).”
Clinical Management of Primary Biliary Cholangitis—Strategies and Evolving Trends
Gao, L., Wang, L., Woo, E., He, X., Yang, G., Bowlus, C., Leung, P. S. C., & Gershwin, M. E. (2020) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-019-08772-7 · Cited by 39
Carambia, A., Gottwick, C., Schwinge, D., Stein, S., Digigow, R., Şeleci, M., Mungalpara, D., Heine, M., Schuran, F. A., Corban, C., et al. (2021) · Immunology · doi:10.1111/imm.13298 · Cited by 30
Metadata
- Authors
- Pearson, R. M., Podojil, J. R., Shea, L. D., King, N. J. C., Miller, S. D., & Getts, D. R.
- Venue
- Nanomedicine: Nanotechnology, Biology and Medicine
- Publisher
- Elsevier BV
- Published
- 2019-06
- Volume
- 18
- Pages
- 282-291
- ISSN
- 1549-9634 (ISSN-L)
- OpenAlex
- W2897020726
- Cited by
- 81
- References
- 3
- FWCI
- 3.58
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Overcoming challenges in treating autoimmuntity: Development of tolerogenic immune-modifying nanoparticles. https://app.cochat.ai/papers/10.1016/j.nano.2018.10.001
- The paper
- Pearson, R. M., Podojil, J. R., Shea, L. D., King, N. J. C., Miller, S. D., & Getts, D. R. (2019). Overcoming challenges in treating autoimmuntity: Development of tolerogenic immune-modifying nanoparticles. Nanomedicine: Nanotechnology, Biology and Medicine. https://doi.org/10.1016/j.nano.2018.10.001
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.